
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is well-positioned for long-term growth, particularly with the upcoming commercialization of its G7 15-day continuous glucose monitoring system. The company's strategy includes integration with insulin pumps from Insulet and Tandem, enhancing its product offerings and attracting a broader patient base. Additionally, continued adoption of DexCom products among both insulin-using and non-insulin-using diabetic populations supports a positive financial outlook.
Bears say
DexCom's financial outlook is tempered by a downward revision of revenue and adjusted EPS projections for 2026, with estimates now at $5.386 billion and $2.69, respectively, a decrease from previous figures of $5.646 billion and $2.91. The company's anticipated growth rate is also declining, with the new projection reflecting only a 16.4% year-over-year increase, compared to an earlier expectation of 22.0%. Additionally, potential regulatory delays pose further risks to future revenue generation, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares